Humphries M J, Yasuda Y, Olden K, Yamada K M
Howard University Cancer Center, Washington, DC 20060.
Ciba Found Symp. 1988;141:75-93. doi: 10.1002/9780470513736.ch5.
Adhesion to specific extracellular matrix molecules appears to be an important prerequisite for successful target organ colonization by metastasizing tumour cells. Interference in the adhesive function of malignant cells with antiadhesive agents is therefore one potential approach for preventing metastasis. Recently, synthetic peptides taken from the cell interaction sites of fibronectin have been characterized as inhibitors of cellular adhesion in vitro. Using these antiadhesive probes we have examined the role of cell adhesion to fibronectin in tumour metastasis using the B16-F10 murine melanoma model system. Two sequences from the IIICS cell-binding domain, the 25-mer CS1 peptide and the tetrapeptide Arg-Glu-Asp-Val (REDV), had no detectable activity, but the pentapeptide Gly-Arg-Gly-Asp-Ser (GRGDS), an active sequence from the central cell-binding domain, exhibited potent, dose-dependent inhibition, indicating a role for this cell recognition determinant in tumour metastasis. Under appropriate conditions GRGDS treatment afforded remarkable protection to the host; mice injected with melanoma cells and peptide were still alive 15 months after injection whereas mice injected with melanoma cells alone died within six weeks. Kinetic analyses of the retention of tumour cells in the lungs and of the vascular clearance rate of labelled GRGDS predict an early time frame of activity for the peptide. From the results of a variety of in vitro invasion and migration assays it appears that GRGDS may interfere with multiple, fibronectin-mediated adhesive and migratory events at different points of the metastatic cascade. In preliminary studies designed to optimize the therapeutic usefulness of GRGDS-like agents, peptide conjugates have been found to possess enhanced antiadhesive activity as well as an extended vascular clearance rate. In the future, therefore, these or related peptide derivatives may be potentially useful agents for the prevention of tumour metastasis.
对特定细胞外基质分子的黏附似乎是转移性肿瘤细胞成功定殖于靶器官的重要前提条件。因此,用抗黏附剂干扰恶性细胞的黏附功能是预防转移的一种潜在方法。最近,从纤连蛋白的细胞相互作用位点提取的合成肽已被鉴定为体外细胞黏附的抑制剂。我们使用B16-F10小鼠黑色素瘤模型系统,利用这些抗黏附探针研究了细胞对纤连蛋白的黏附在肿瘤转移中的作用。来自IIICS细胞结合结构域的两个序列,即25肽CS1和四肽精氨酸-谷氨酸-天冬氨酸-缬氨酸(REDV),没有可检测到的活性,但来自中央细胞结合结构域的活性序列五肽甘氨酸-精氨酸-甘氨酸-天冬氨酸-丝氨酸(GRGDS)表现出强效的、剂量依赖性抑制作用,表明该细胞识别决定簇在肿瘤转移中发挥作用。在适当条件下,GRGDS处理为宿主提供了显著的保护;注射黑色素瘤细胞和肽的小鼠在注射后15个月仍然存活,而仅注射黑色素瘤细胞的小鼠在六周内死亡。对肺部肿瘤细胞滞留情况和标记GRGDS的血管清除率的动力学分析预测了该肽的早期活性时间框架。从各种体外侵袭和迁移试验的结果来看,GRGDS可能在转移级联反应的不同点干扰多种由纤连蛋白介导的黏附和迁移事件。在旨在优化类GRGDS药物治疗效用的初步研究中,已发现肽缀合物具有增强的抗黏附活性以及延长的血管清除率。因此,在未来,这些或相关的肽衍生物可能是预防肿瘤转移的潜在有用药物。